Zura Bio (ZURA) Projected to Release Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Zura Bio to announce earnings of ($0.22) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 7:00 AM ET.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). On average, analysts expect Zura Bio to post ($0.82) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

Zura Bio Stock Up 0.8%

Shares of ZURA opened at $4.02 on Thursday. The firm has a market cap of $385.24 million, a price-to-earnings ratio of -3.59 and a beta of 0.03. The company’s fifty day moving average is $4.53 and its 200-day moving average is $5.22. Zura Bio has a 12 month low of $3.25 and a 12 month high of $7.44.

Analyst Upgrades and Downgrades

ZURA has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. William Blair assumed coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Weiss Ratings upgraded Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, October 28th. Guggenheim reaffirmed a “buy” rating on shares of Zura Bio in a research report on Friday, October 30th. Finally, Wedbush upped their price target on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $17.00.

About Zura Bio

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.